Pfizer Inc said on Friday it could file in late November for U.S. authorization of the COVID-19 vaccine it is developing, suggesting that a vaccine could potentially be available in the United States by the end of the year. | Video
U.S. President Donald Trump and the head of the Centers for Disease Control and Prevention (CDC) have disagreed about when a COVID-19 vaccine would become widely available. Trump has said enough vaccine would be available for every American by April, while the CDC director said vaccines were likely to reach the general public around mid-2021, an assessment more in line with most experts.
(This Oct. 13 story corrects the headline and paragraphs 1 and 9 to show the federal government, not Eli Lilly, made the decision to pause a clinical trial of the company’s antibody drug) | Video
Eli Lilly & Co on Wednesday said other trials of its experimental coronavirus antibody therapy remain on track after a government-run study testing the treatment in hospitalized COVID-19 patients was paused due to safety concerns. | Video
NEW YORK The Takeda Pharmaceutical Co-led group that is developing a blood plasma treatment for COVID-19 has started manufacturing while the late-stage trial to determine whether it works is ongoing, Takeda Chief Executive Christophe Weber said on Monday.